Trial reportArchives of dermatological research2023
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.
Trial report in Archives of dermatological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023.Cureus · 2026Review
- Evaluation of Melanocytes and T-cells in Vitiliginous Skin Pre- and Post-Narrow-Band UVB Phototherapy.Indian dermatology online journal · 2026Article
- From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.Clinical, cosmetic and investigational dermatology · 2026Review
- PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.The Journal of clinical and aesthetic dermatology · 2025Review
- Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.Frontiers in pharmacology · 2025Review
- Up-and-Coming Drugs for the Treatment of Vitiligo.Annals of dermatology · 2024Review
- The role of aryl hydrocarbon receptor in vitiligo: a review.Frontiers in immunology · 2024Review
- Article
- Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improved repigmentation of generalized vitiligo in skin types IV-VI has been reported in clinical response to combined therapy with apremilast and narrowband (NB)-UVB; however, tissue responses to combined therapy versus NB-UVB monotherapy have not been elucidated. We compared the change from baseline in cellular and molecular markers in vitiligo skin after combined therapy versus NB-UVB monotherapy. We assessed lesional and nonlesional skin samples from enrolled subjects and evaluated for immune infiltrates, inflammatory, and melanogenesis-related markers which were compared across different treatment groups. Combined therapy resulted in significant reduction of CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.